Amicar (Aminocaproic Acid)
برای این دارو، اطلاعات عمومی (فارسی) یافت نشد . برای افزودن اطلاعات فارسی به این دارو کلیک نمایید.
Amicar (Aminocaproic Acid)

AMICAR®
(aminocaproic acid) Oral Solution and Tablets

DRUG DESCRIPTION

AMICAR (aminocaproic acid) is 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis.

Its chemical structure is:

 AMICAR® (aminocaproic acid)  Structural Formula Illustration

AMICAR (aminocaproic acid) is soluble in water, acid, and alkaline solutions; it is sparingly soluble in methanol and practically insoluble in chloroform.

AMICAR (aminocaproic acid) Oral Solution for oral administration, contains 0.25 g/mL of aminocaproic acid with methylparaben 0.20%, propylparaben 0.05%, edetate disodium 0.30% as preservatives and the following inactive ingredients: sodium saccharin, sorbitol solution, citric acid anhydrous, natural and artificial raspberry flavor and an artificial bitterness modifier.

Each AMICAR (aminocaproic acid) Tablet, for oral administration contains 500 mg or 1000 mg of aminocaproic acid and the following inactive ingredients: povidone, crospovidone, stearic acid, and magnesium stearate.

What are the possible side effects of aminocaproic acid (Amicar)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using aminocaproic acid and call your doctor at once if you have a serious side effect such as:

  • sudden numbness or weakness, especially on one side of the body;
  • sudden headache, confusion, problems with vision, speech, or balance;
  • sudden cough, rapid breathing, fast heart rate;
  • pain or swelling in one or both legs;
  • muscle pain, tenderness, or weakness with fever or flu...

Read All Potential Side Effects and See Pictures of Amicar »

What are the precautions when taking aminocaproic acid (Amicar)?

Before taking aminocaproic acid, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as paraben preservatives in the liquid product), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: bleeding of unknown cause, a certain bleeding condition (disseminated intravascular coagulation-DIC), a certain clotting problem (active intravascular clotting), a certain cause of blood in the urine (upper urinary tract bleeding).

Before using this medication, tell your doctor or pharmacist your medical...

Read All Potential Precautions of Amicar »

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

INDICATIONS

AMICAR (aminocaproic acid) is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In lifethreatening situations, transfusion of appropriate blood products and other emergency measures may be required.

Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix.

Urinary fibrinolysis, usualIy a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS.)

DOSAGE AND ADMINISTRATION

An identical dosage regimen may be followed by administering AMICAR (aminocaproic acid) Tablets or AMICAR (aminocaproic acid) Oral Solution as follows:

For the treatment of acute bleeding syndromes due to elevated fibrinolytic activity, it is suggested that 5 AMICAR (aminocaproic acid) 1000 mg Tablets or 10 AMICAR (aminocaproic acid) 500 mg Tablets (5 g) or 20 milliliter of AMICAR (aminocaproic acid) Oral Solution (5 g) be administered during the first hour of treatment, followed by a continuing rate of 1 AMICAR (aminocaproic acid) 1000 mg Tablet or 2 AMICAR (aminocaproic acid) 500 mg Tablets (1 g) or 5 milliliter of AMICAR (aminocaproic acid) Oral Solution (1.25 g) per hour. This method of treatment would ordinarily be continued for about 8 hours or until the bleeding situation has been controlled.

HOW SUPPLIED

AMICAR®
(aminocaproic acid)

AMICAR (aminocaproic acid) Oral Solution, 0.25 g/mL

Each mL of raspberry-flavored oral solution contains 0.25 g/mL of aminocaproic acid.

16 Fl. Oz. (473 mL) Bottle – NDC 66479-023-56

Store Between 15°-30°C (59°-86°F); Dispense in Tight Containers; Do Not Freeze.

AMICAR (aminocaproic acid) 500 mg Tablets

Each round, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 10 on the right, contains 500 mg of aminocaproic acid.

Bottle of 100 – NDC 66479-021-82

Store Between 15°-30°C (59°-86°F); Dispense in Tight Containers.

AMICAR (aminocaproic acid) 1000 mg Tablets

Each oblong, white tablet, engraved with XP on one side and scored on the other with A to the left of the score and 20 on the right, contains 1000 mg of aminocaproic acid.

Bottle of 100 – NDC 66479-022-82

Store Between 15°-30°C (59°-86°F); Dispense in Tight Containers.

Marketed by : Xanodyne Pharmaceuticals, Newport, KY 41071, Rev. 09/08.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

SIDE EFFECTS

AMICAR (aminocaproic acid) is generally well tolerated. The following adverse experiences have been reported:

General

Edema, headache, malaise.

Hypersensitivity Reactions

Allergic and anaphylactoid reactions, anaphylaxis.

Cardiovascular

Bradycardia, hypotension, peripheral ischemia, thrombosis.

Gastrointestinal

Abdominal pain, diarrhea, nausea, vomiting.

Hematologic

Agranulocytosis, coagulation disorder, leukopenia, thrombocytopenia.

Musculoskeletal

CPK increased, muscle weakness, myalgia, myopathy (see WARNINGS), myositis, rhabdomyolysis.

Neurologic

Confusion, convulsions, delirium, dizziness, hallucinations, intracranial hypertension, stroke, syncope.

Respiratory

Dyspnea, nasal congestion, pulmonary embolism.

Skin

Pruritis, rash.

Special Senses

Tinnitus, vision decreased, watery eyes.

Urogenital

BUN increased, renal failure. There have been some reports of dry ejaculation during the period of AMICAR (aminocaproic acid) treatment. These have been reported to date only in hemophilia patients who received the drug after undergoing dental surgical procedures. However, this symptom resolved in all patients within 24 to 48 hours of completion of therapy.

Read the Amicar (aminocaproic acid) Side Effects Center for a complete guide to possible side effects »

DRUG INTERACTIONS

Drug Laboratory Test Interactions

Prolongation of the template bleeding time has been reported during continuous intravenous infusion of AMICAR (aminocaproic acid) at dosages exceeding 24 g/day. Platelet function studies in these patients have not demonstrated any significant platelet dysfunction. However, in vitro studies have shown that at high concentrations (7.4 mMol/L or 0.97 mg/mL and greater) aminocaproic acid inhibits ADP and collagen-induced platelet aggregation, the release of ATP and serotonin, and the binding of fibrinogen to the platelets in a concentration-response manner. Following a 10 g bolus of AMICAR (aminocaproic acid) , transient peak plasma concentrations of 4.6 mMol/L or 0.60 mg/mL have been obtained. The concentration of AMICAR (aminocaproic acid) necessary to maintain inhibition of fibrinolysis is 0.99 mMol/L or 0.13 mg/mL. Administration of a 5 g bolus followed by 1 to 1.25 g/hr should achieve and sustain plasma levels of 0.13 mg/mL. Thus, concentrations which have been obtained in vivo clinically in patients with normal renal function are considerably lower than the in vitro concentrations found to induce abnormalities in platelet function tests. However, higher plasma concentrations of AMICAR (aminocaproic acid) may occur in patients with severe renal failure.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

WARNINGS

In patients with upper urinary tract bleeding, AMICAR (aminocaproic acid) administration has been known to cause intrarenal obstruction in the form of glomerular capillary thrombosis or clots in the renal pelvis and ureters. For this reason, AMICAR (aminocaproic acid) should not be used in hematuria of upper urinary tract origin, unless the possible benefits outweigh the risk.

Subendocardial hemorrhages have been observed in dogs given intravenous infusions of 0.2 times the maximum human therapeutic dose of AMICAR (aminocaproic acid) and in monkeys given 8 times the maximum human therapeutic dose of AMICAR (aminocaproic acid) .

Fatty degeneration of the myocardium has been reported in dogs given intravenous doses of AMICAR (aminocaproic acid) at 0.8 to 3.3 times the maximum human therapeutic dose and in monkeys given intravenous doses of AMICAR (aminocaproic acid) at 6 times the maximum human therapeutic dose.

Rarely, skeletal muscle weakness with necrosis of muscle fibers has been reported following prolonged administration. Clinical presentation may range from mild myalgias with weakness and fatigue to a severe proximal myopathy with rhabdomyolysis, myoglobinuria, and acute renal failure. Muscle enzymes, especially creatine phosphokinase (CPK) are elevated. CPK levels should be monitored in patients on long-term therapy. AMICAR (aminocaproic acid) administration should be stopped if a rise in CPK is noted. Resolution follows discontinuation of AMICAR (aminocaproic acid) ; however, the syndrome may recur if AMICAR (aminocaproic acid) is restarted.

The possibility of cardiac muscle damage should also be considered when skeletal myopathy occurs. One case of cardiac and hepatic lesions observed in man has been reported. The patient received 2 g of aminocaproic acid every 6 hours for a total dose of 26 g. Death was due to continued cerebrovascular hemorrhage. Necrotic changes in the heart and liver were noted at autopsy.

PRECAUTIONS

General

AMICAR (aminocaproic acid) inhibits both the action of plasminogen activators and to a lesser degree, plasmin activity. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia).1

Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed in vivo may not undergo spontaneous Iysis as do normal clots.

Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of antifibrinolytic agents in the treatment of subarachnoid hemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear.

Aminocaproic acid should not be administered with Factor IX Complex concentrates or Anti-Inhibitor Coagulant concentrates, as the risk of thrombosis may be increased.

Laboratory Tests

The use of AMICAR (aminocaproic acid) should be accompanied by tests designed to determine the amount of fibrinolysis present. There are presently available: (a) general tests such as those for the determination of the Iysis of a clot of blood or plasma; and (b) more specific tests for the study of various phases of the fibrinolytic mechanisms. These latter tests include both semiquantitative and quantitative techniques for the determination of profibrinolysin, fibrinolysin, and antifibrinolysin.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate the carcinogenic potential of AMICAR (aminocaproic acid) and studies to evaluate its mutagenic potential have not been conducted. Dietary administration of an equivalent of the maximum human therapeutic dose of AMICAR (aminocaproic acid) to rats of both sexes impaired fertility as evidenced by decreased implantations, litter sizes and number of pups born.

Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with AMICAR (aminocaproic acid) . It is also not known whether AMICAR (aminocaproic acid) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. AMICAR (aminocaproic acid) should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when AMICAR (aminocaproic acid) is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

REFERENCES

1 Stefanini M, Dameshek W: The Hemorrhagic Disorders, Ed. 2, New York, Grune and Stratton; 1962:510-514.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

OVERDOSE

A few cases of acute overdosage with AMICAR (aminocaproic acid) administered intravenously have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. One patient with a history of brain tumor and seizures experienced seizures after receiving an 8 gram bolus injection of AMICAR (aminocaproic acid) . The single dose of AMICAR (aminocaproic acid) causing symptoms of overdosage or considered to be life-threatening is unknown. Patients have tolerated doses as high as 100 grams while acute renal failure has been reported following a dose of 12 grams.

The intravenous and oral LD50 of AMICAR (aminocaproic acid) were 3.0 and 12.0 g/kg, respectively, in the mouse and 3.2 and 16.4 g/kg, respectively, in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog. On intravenous administration, tonic-clonic convulsions were observed in dogs and mice.

No treatment for overdosage is known, although evidence exists that AMICAR (aminocaproic acid) is removed by hemodialysis and may be removed by peritoneal dialysis. Pharmacokinetic studies have shown that total body clearance of AMICAR (aminocaproic acid) is markedly decreased in patients with severe renal failure.

CONTRAINDICATIONS

AMICAR (aminocaproic acid) should not be used when there is evidence of an active intravascular clotting process.

When there is uncertainty as to whether the cause of bleeding is primary fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be made before administering AMICAR (aminocaproic acid) .

The following tests can be applied to differentiate the two conditions:

  • Platelet count is usually decreased in DIC but normal in primary fibrinolysis.
  • Protamine paracoagulation test is positive in DIC; a precipitate forms when protamine sulfate is dropped into citrated plasma. The test is negative in the presence of primary fibrinolysis.
  • The euglobulin clot Iysis test is abnormal in primary fibrinolysis but normal in DIC.

AMICAR (aminocaproic acid) must not be used in the presence of DIC without concomitant heparin.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

CLINICAL PHARMACOLOGY

The fibrinolysis-inhibitory effects of AMICAR (aminocaproic acid) appear to be exerted principally via inhibition of plasminogen activators and to a lesser degree through antiplasmin activity.

In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1). Mean ± SD peak plasma concentrations (164 ± 28 mcg/mL) were reached within 1.2 ± 0.45 hours.

After oral administration, the apparent volume of distribution was estimated to be 23.1 ± 6.6 L (mean ± SD). Correspondingly, the volume of distribution after intravenous administration has been reported to be 30.0 ± 8.2 L. After prolonged administration, AMICAR (aminocaproic acid) has been found to distribute throughout extravascular and intravascular compartments of the body, penetrating human red blood cells as well as other tissue cells.

Renal excretion is the primary route of elimination. Sixty-five percent of the dose is recovered in the urine as unchanged drug and 11% of the dose appears as the metabolite adipic acid. Renal clearance (116 mL/min) approximates endogenous creatinine clearance. The total body clearance is 169 mL/min. The terminal elimination half-life for AMICAR (aminocaproic acid) is approximately 2 hours.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

>

PATIENT INFORMATION

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

Last reviewed on RxList: 3/11/2009
This monograph has been modified to include the generic and brand name in many instances.

Disclaimer

Amicar Consumer

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

AMINOCAPROIC ACID - ORAL

(a-MEE-noe-ka-PROE-ik-AS-id)

COMMON BRAND NAME(S): Amicar

USES: This medication is used to treat severe bleeding caused by problems with the blood clotting system, which helps you to stop bleeding. Aminocaproic acid works by affecting the blood clotting system, thereby slowing/stopping bleeding after surgery, in some bleeding conditions, or in severe liver disease.

HOW TO USE: Take this medication by mouth exactly as directed by your doctor. It is important to take each dose at the correct time for this medication to be most effective. Do not skip any doses or take this medication more often than prescribed.

If you are using the liquid form of this medication, measure your dose with a special measuring spoon or device. Do not use a household spoon because it may not provide the correct dose.

Dosage is based on your medical condition and response to therapy.

Inform your doctor if your condition persists or worsens.

Disclaimer

Amicar Consumer (continued)

SIDE EFFECTS: Headache, stomach pain, loss of appetite, nausea, vomiting, diarrhea, unusual tiredness, dizziness, stuffy nose, or watery eyes may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur: ringing in the ears, vision changes, shortness of breath.

Tell your doctor immediately if any of these rare but very serious side effects occur: muscle pain/weakness, change in the amount of urine, confusion, slow heartbeat, persistent sore throat, unusual bleeding or bruising.

Seek immediate medical attention if any of these rare but very serious side effects occur: chest pain, seizures.

A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

Read the Amicar (aminocaproic acid) Side Effects Center for a complete guide to possible side effects »

PRECAUTIONS: Before taking aminocaproic acid, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as paraben preservatives in the liquid product), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

This medication should not be used if you have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if you have: bleeding of unknown cause, a certain bleeding condition (disseminated intravascular coagulation-DIC), a certain clotting problem (active intravascular clotting), a certain cause of blood in the urine (upper urinary tract bleeding).

Before using this medication, tell your doctor or pharmacist your medical history, especially of: heart disease, liver disease, kidney disease, other blood/bleeding disorders (e.g., hemophilia, uremia).

This drug may make you dizzy. Do not drive, use machinery, or do any activity that requires alertness until you are sure you can perform such activities safely. Limit alcoholic beverages.

During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.

It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.

Disclaimer

Amicar Consumer (continued)

DRUG INTERACTIONS: Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: blood clotting factors (e.g., Factor IX complex, anti-inhibitor coagulant complex), hormonal birth control (e.g., the pill, patch, ring), estrogens.

This medication may interfere with certain laboratory tests. Make sure laboratory personnel and all your doctors know that you use this drug.

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: sudden change in amount of urine, seizures.

NOTES: This medication is usually given in the hospital so your condition can be monitored closely until bleeding is controlled.

Do not share this medication with others.

Laboratory and/or medical tests (e.g., platelet counts, blood clotting tests, CPK levels) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

MISSED DOSE: It is important to take each dose at the scheduled time. If you miss a dose, take it as soon as you remember, and contact your doctor to establish a new dosing schedule. Do not double the dose to catch up unless directed to do so by your doctor.

STORAGE: Store in a tightly closed container at room temperature between 59-86 degrees F (15-30 degrees C) away from light and moisture. Do not freeze liquid forms of this medication. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-800-854-1166 (USA) or 1-800-668-1507 (Canada).

Information last revised October 2010. Copyright(c) 2010 First Databank, Inc.

Amicar Patient Information Including Side Effects

Brand Names: Amicar

Generic Name: aminocaproic acid (Pronunciation: a MEE noe ka PROE ik AS id)

What is aminocaproic acid (Amicar)?

Aminocaproic acid is a man-made form of a protein that occurs naturally in the body and helps the blood clot.

Aminocaproic acid is used to treat bleeding episodes in people with certain medical conditions such as aplastic anemia (lack of blood cells and platelets), cirrhosis of the liver, placenta abruptio (early separation of the placenta in pregnancy), urinary bleeding, and certain types of cancer. Aminocaproic acid is also used to prevent bleeding after heart surgery or placement of a shunt near the liver to control high blood pressure

Aminocaproic acid may also be used for purposes not listed in this medication guide.

Amicar 500 mg

round, white, imprinted with LL, A 10

Aminocaproic Acid 500 mg-VER

round, white, imprinted with VP 045

What are the possible side effects of aminocaproic acid (Amicar)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using aminocaproic acid and call your doctor at once if you have a serious side effect such as:

  • sudden numbness or weakness, especially on one side of the body;
  • sudden headache, confusion, problems with vision, speech, or balance;
  • sudden cough, rapid breathing, fast heart rate;
  • pain or swelling in one or both legs;
  • muscle pain, tenderness, or weakness with fever or flu symptoms and dark colored urine;
  • urinating less than usual or not at all;
  • drowsiness, confusion, mood changes, increased thirst, loss of appetite, nausea and vomiting;
  • swelling, weight gain, feeling short of breath;
  • slow heart rate, trouble breathing, feeling like you might pass out;
  • numbness or tingling in your arms or legs;
  • easy bruising or bleeding, purple or red pinpoint spots under your skin; or
  • confusion, hallucinations;

Less serious side effects may include:

  • mild muscle pain or weakness;
  • headache, tired feeling;
  • nausea, vomiting, stomach pain, diarrhea;
  • (in men) decreased amount of semen when having an orgasm;
  • stuffy nose, watery eyes
  • vision problems, ringing in your ears; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Amicar (aminocaproic acid) Side Effects Center for a complete guide to possible side effects »

What is the most important information I should know about aminocaproic acid (Amicar)?

You should not use this medication if you are allergic to it. Your doctor will perform blood tests to make sure you do not have other conditions that would prevent you from safely using aminocaproic acid.

Before you use aminocaproic acid, tell your doctor if you have kidney disease, or a history of stroke or blood clot.

To be sure this medication is not causing harmful effects, your blood cells and kidney function may need to be tested often. Do not miss any follow-up visits to your doctor for blood or urine tests.

Tell your doctor if you also use any clotting medications such as factor IX complex or anti-inhibitor coagulant complex (Autoplex, Feiba VH).

Stop taking aminocaproic acid and call your doctor if you have a serious side effect such as sudden numbness or weakness, pain or swelling in your legs, sudden cough, feeling short of breath, muscle tenderness or weakness with flu symptoms and dark colored urine, swelling, weight gain, urinating less than usual or not at all, sudden headache or confusion, or problems with vision, speech, or balance.

Do not give this medication to a child.

Side Effects Centers

Amicar Patient Information including How Should I Take

What should I discuss with my health care provider before using aminocaproic acid (Amicar)?

You should not use this medication if you are allergic to it. Your doctor will perform blood tests to make sure you do not have other conditions that would prevent you from safely using aminocaproic acid.

To make sure you can safely take aminocaproic acid, tell your doctor if you have any of these other conditions:

  • kidney disease; or
  • a history of stroke or blood clots;

FDA pregnancy category C. It is not known whether aminocaproic acid will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.

It is not known whether aminocaproic acid passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Do not give this medication to a child.

How should I use aminocaproic acid (Amicar)?

Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Start using the medication at the first sign of a bleeding episode. Your first dose may be much higher than the doses you use later on. Follow your doctor's dosing instructions very carefully.

Treatment with aminocaproic acid is usually continued hourly for 8 hours or until the bleeding has stopped.

Aminocaproic acid is either taken by mouth or injected into a vein through an IV.

You may need to first use the injection form and then use an oral form (tablet or liquid). Follow your doctor's instructions.

A healthcare provider will give you this injection. You may be shown how to use an IV at home. Do not self-inject this medicine if you do not fully understand how to give the injection and properly dispose of used needles, IV tubing, and other items used to inject the medicine.

Take the aminocaproic acid tablets with a full glass (8 ounces) of water.

Measure the oral syrup with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

The injectable form of aminocaproic acid must be mixed with a liquid (diluent) before using it. If you are using the injections at home, be sure you understand how to properly mix and store the medication.

Do not use the aminocaproic acid injection if it has changed colors or has particles in it. Call your doctor for a new prescription.

To be sure this medication is not causing harmful effects, your blood cells and kidney function may need to be tested often. Aminocaproic acid can have long-lasting effects on your body. Do not miss any follow-up visits to your doctor for blood or urine tests.

Store this medication at cool room temperature, away from heat and moisture.

Side Effects Centers

Amicar Patient Information including If I Miss a Dose

What happens if I miss a dose (Amicar)?

Since aminocaproic acid is used as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Amicar)?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include urinating less than usual, feeling light-headed, or fainting.

What should I avoid while taking aminocaproic acid (Amicar)?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect aminocaproic acid (Amicar)?

Tell your doctor about all other medications you use, especially:

  • factor IX complex(Bebulin VH, Konyne 80, Profilnine SD, Proplex T); or
  • anti-inhibitor coagulant complex (Autoplex, Feiba VH).

This list is not complete and other drugs may interact with aminocaproic acid. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about aminocaproic acid.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2012 Cerner Multum, Inc. Version: 2.02. Revision date: 12/15/2010.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers

توزیع کنندگان این دارو
شرکت های تولید کننده یا وارد کننده دارو

دارونـــما
نوآوری برای سلامت

طراحی و اجرا M.Ramezani
ارتباط با ما Info@darunama.com